Navigation Links
Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
Date:11/28/2007

- RDEA806 Shown to Produce Statistically Significant, Dose-Dependent

Reduction in Serum Uric Acid in Phase 1 Clinical Study - Phase 2 Efficacy Study in Gout Patients to Start in the First Half of

2008

CARLSBAD, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the initiation of a new clinical development program directed toward the treatment of gout. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream. These abnormally elevated levels lead to the deposition of uric acid crystals in and around the connective tissue of the joints and in the kidneys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). An estimated 3-5 million people in the U.S. suffer from gout, which is the most common form of inflammatory arthritis in men over 40.

"We are extremely excited to be launching this new development initiative," said Barry D. Quart, Pharm.D., President and Chief Executive Officer. "Gout represents a major medical challenge in the U.S. and throughout the world, and, with no new treatments approved by the U.S. Food and Drug Administration for the underlying cause of gout in the past 40 years, there is a significant need for new therapeutic agents."

Phase 1 Experience

Earlier this year, Ardea conducted a comprehensive Phase 1 program in 98 healthy volunteers to evaluate the safety and pharmacokinetics of RDEA806, its lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... , Oct. 22, 2014  Quest Diagnostics (NYSE: ... information services, today announced that its Board of Directors ... a director, effective December 1, 2014. Including Dr. Leiden, ... is the Chairman, President and CEO of Vertex Pharmaceuticals. ... scientific and commercial experience in the pharmaceutical and biotechnology ...
(Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Oct. 13 The Care Continuum Alliance ... Award for the "Greatest Impact on Health" at ...  The ALL/PHASE protocol, which utilizes low-cost and generic medications ... successfully implemented in Kaiser Permanente communities, including those served ...
... Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna -- OOSTERHOUT, Netherlands, Oct. 13 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 4Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 5Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 6Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 7Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 8Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 9
(Date:10/25/2014)... -- Arriving home safe and sound is one of the ... sure that costumes and goody bags have reflective strips that ... medicine doctor at Meadowlands Hospital Medical Center in Secaucus, N.J. ... should be flame-resistant, Davis said. He offers these others ... it on a small area of skin first to ensure ...
(Date:10/25/2014)... 2014 The Wehrman Collaborative, ... IT-accessibility for disabled users by disabled users, has ... to Mackin Educational Resources of Burnsville, Minnesota, for ... and to the Minnesota Alliance for Patient Safety ... Medicine" website. Both organizations have met ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Current osteoporosis screening guidelines ... women at risk for osteoporosis-related fractures, a new ... fractures, we need tools that help us accurately ... that we can target these at-risk people for ... of medicine in the division of general internal ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... (April 1, 2009) -- Individuals diagnosed with a brain ... and veins -- are at increased risk of vessel ... Traditionally, doctors have prescribed preventive interventions like surgery, but ... actually increase risk of a rupture, at least in ...
... Texas, April 1 ULURU ... announced today that clinical evidence on the treatment of ... physical properties of Altrazeal(TM) Silver will be presented at the ... The work will be presented in podium presentations and ...
... for Innovative Design, Positive Impact on Lives of People ... OmniPod(R) Insulin Management System, designed and produced by Insulet ... 2009 Edison Best New Product Award(TM). The product was ... Medical category in recognition of its innovative design that ...
... and TRENTON, N.J., April 1 The Providence ... announced that its LogistiCare subsidiary, the nation,s largest ... notice of award from the New Jersey Department ... and Health Services (DMAHS), to provide basic non-emergency ...
... ,not overwhelming, applies only to those with particular gene ... with advanced colorectal cancer were modestly helped by the ... particular gene mutation, a new study reports. , , ... metastatic colorectal cancer that could not be surgically removed. ...
... readmitted within a year, study finds , , WEDNESDAY, April ... discharged from the hospital is readmitted within 30 days, ... a year, a new study finds. , The groundbreaking ... that researchers believe could be prevented through better care ...
Cached Medicine News:Health News:Is intervention beneficial for brain vessel malformations? 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 2Health News:Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009 3Health News:OmniPod(R) Insulin Management System Wins 2009 Edison Best New Product Award 2Health News:OmniPod(R) Insulin Management System Wins 2009 Edison Best New Product Award 3Health News:Providence's LogistiCare Subsidiary Receives Notice of Award for Five Year Approximately $300 Million New Jersey Statewide Non-Emergency Medical Transportation Contract 2Health News:Providence's LogistiCare Subsidiary Receives Notice of Award for Five Year Approximately $300 Million New Jersey Statewide Non-Emergency Medical Transportation Contract 3Health News:Erbitux May Help Some With Colorectal Cancer 2Health News:Erbitux May Help Some With Colorectal Cancer 3Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
The Restoration GAP system addresses complex acetabular reconstruction with morselized graft through immobilization and proper compressive loading, the two mechanical factors influencing the integrat...
Medicine Products: